Recife, Brazil is bolstering its defenses against bronchiolitis, a common respiratory illness affecting young children, through a multi-pronged approach involving vaccination of pregnant women and the administration of a new antibody treatment for infants. These initiatives, recently implemented across the city’s public health system (SUS), aim to reduce the burden of severe cases and hospitalizations, particularly during peak season.
Bronchiolitis, often caused by the Respiratory Syncytial Virus (RSV), poses a significant threat to infants and young children, leading to breathing difficulties and, in severe cases, requiring hospitalization. The implementation of these preventative measures represents a crucial step in safeguarding the health of the region’s most vulnerable population. According to the Ministry of Health, RSV is responsible for approximately 75% of bronchiolitis cases and 40% of pneumonia cases in children under two years old.
Starting in December 2025, pregnant women in Recife began receiving vaccinations against RSV, designed to provide passive immunity to their newborns. This vaccination, administered from the 28th week of gestation onwards, encourages the mother to produce antibodies that are then transferred to the baby, offering protection during the first vulnerable months of life. The city aims to vaccinate 80% of its approximately 18,753 pregnant residents with this preventative measure. To receive the vaccine, individuals need to present their vaccination card, CPF or SUS card, and documentation confirming their gestational age.
New Antibody Treatment Now Available Through SUS
In a significant expansion of access, ten public health facilities in Recife have begun offering nirsevimab, a monoclonal antibody that provides direct protection against RSV. Previously available only in the private healthcare sector due to its cost, nirsevimab is now incorporated into the SUS catalog, making it accessible to a wider range of families. The antibody offers protection for 5 to 6 months after administration.
This new antibody treatment represents a shift in preventative care, offering a targeted approach to protecting infants directly. The implementation of nirsevimab alongside the maternal vaccination program demonstrates a comprehensive strategy to combat bronchiolitis in Recife. The initiative comes as Brazil registered 43,200 cases of Severe Acute Respiratory Syndrome (SRAG) caused by RSV as of November 22, 2025.
Regional Efforts to Combat Bronchiolitis
Recife is not alone in its efforts to protect infants from bronchiolitis. Neighboring Alagoas state has also initiated vaccination of newborns against the virus, and Ribeirão Preto is beginning immunization of babies against the respiratory virus. These coordinated efforts across the region highlight the widespread concern and proactive response to the threat of bronchiolitis.
The state of Pernambuco received 30,700 doses of the RSV vaccine from the Ministry of Health, with Recife initially receiving 4,470 doses. Health officials are emphasizing the importance of vaccination, particularly as bronchiolitis is a leading cause of infant hospitalization. The Diario de Pernambuco reported that less than 40% of pregnant women in the state had been immunized as of a recent update, underscoring the need for continued outreach, and education.
Looking ahead, health authorities will continue to monitor vaccination rates and the incidence of bronchiolitis in Recife and throughout Pernambuco. Further data analysis will be crucial to assess the effectiveness of these new preventative measures and to inform future public health strategies. Continued efforts to raise awareness among pregnant women and parents will be essential to maximize the impact of these initiatives.
This is a developing public health story. Share your thoughts and experiences in the comments below.
Disclaimer: This article provides informational content about health topics and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.
